SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Inclusion Criteria: * History of primary mucosal or acral/lentiginous melanoma * Histologically documented stage III unresectable or IV metastatic melanoma * ECOG Performance Status 0,1 or 2 * Estimated life expectancy of 6 months or greater * 18 years of age or older * Lab values as outlined in protocol * Tumor blocks or slides must be available of either primary or metastatic tumor site for c-kit mutation testing * Negative pregnancy test within 48 hours of starting treatment * At least one measurable site of disease as defined by at least 1cm in greatest dimension Exclusion Criteria: * Severe and/or uncontrolled medical disease * Pregnant or nursing mothers * Known brain metastasis. History of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening CT or MRI scan * Less than 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or cervical carcinoma in situ * Grade III/IV cardiac problems as defined by the New York Heart Association Criteria * Ongoing cardiac dysrhythmias of grade 2 or greater, atrial fibrillation, QTc interval \>450msec for males of \>470 msec for females * Hypertension that cannot be controlled by medication * Any of the following within 12 months prior to starting treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism * NCI CTCAE version 3.0 grade 3 hemorrhage within 4 weeks of starting the study treatment * Concurrent treatment with warfarin * Prior treatment with SU011248 or any other antiangiogenic agent * No H2 blockers or proton pump inhibitors * Known chronic liver disease * Known HIV infection * Previous radiotherapy to 25% or more of the bone marrow and/or radiation therapy within 4 weeks prior to study entry * Major surgery within 4 weeks prior to study entry * Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication